Positive Early Trial Results for Micron's Needle-Free Vaccines in Kids Published in The Lancet

Micron Biomedical, a pioneering firm in the field of life sciences, has made a significant stride with its breakthrough dissolvable microarray technology. The company's innovative approach to drug and vaccine delivery has been acknowledged for its potential to revolutionize healthcare, particularly in eradicating diseases in resource-limited settings. The World Health Organization and other health bodies have placed this technology at the forefront of their priorities.

In a recent development, Micron Biomedical has reported positive results from the Phase 1/2 clinical trials of its measles and rubella vaccine, which were published in the prestigious medical journal, The Lancet. The study, a first of its kind, involved participants ranging from adults to infants as young as nine months. The microarray technology has been lauded for its high safety and immunogenicity, indicating that it could be a game-changer in humanitarian contexts.

The CEO of Micron Biomedical, Steven Damon, highlighted the transformative impact of needle-free pharmaceuticals, emphasizing their potential to eliminate diseases in low- and middle-income countries and to enhance accessibility in developed nations and for military use. The publication in The Lancet signifies a crucial recognition of the technology's safety and efficacy by the scientific community.

In regions where measles is a leading cause of death, often due to inadequate infrastructure for vaccine distribution and storage, Micron's needle-free measles-rubella vaccine offers a solution. It diminishes the reliance on cold chain requirements and facilitates self-administration, thereby addressing the pain-free delivery of vaccines.

James Goodson, a Senior Scientist and Epidemiologist at the CDC, underscored the importance of next-generation vaccines in achieving global measles and rubella elimination. He pointed out that the current vaccination programs often fall short of the 95% target due to various barriers, including the need for travel to vaccination sites, a shortage of trained healthcare professionals, and the challenges of maintaining vaccines at the correct temperature.

The clinical trial conducted by the Medical Research Council Unit in The Gambia was a rigorous, double-blind study that included a diverse age group. The results showed that Micron's MR microarray technology was well-tolerated, safe, and induced a strong immune response similar to that of traditional injections, with no serious adverse events reported.

Furthermore, Micron Biomedical received a substantial grant of $23.6 million from the Bill & Melinda Gates Foundation, which will support the mass production of their needle-free vaccines and the commercialization of the measles-rubella vaccine for children as young as nine months, pending regulatory approval.

Beyond the measles and rubella vaccine, Micron's microarray technology has shown promise in influenza and is currently under evaluation for other infectious diseases, contraception, diabetes treatment, and weight loss applications.

The dissolvable microarray "button" used by Micron is a simple and painless method of administering vaccines or therapeutics. It is applied to the skin and delivers the substance directly into the dermal layers. The technology is thermostable, eliminating the need for cold chain logistics, and can be easily disposed of as non-sharp waste.

Measles and rubella, both serious viral diseases, can lead to severe complications or even death. They are preventable through vaccination, and Micron Biomedical's technology aims to make these vaccines more accessible and easier to administer globally.

Micron Biomedical is committed to improving global health outcomes through its innovative, injection-free, and painless drug and vaccine administration technology. The company is supported by partnerships and funding from various private, public, and philanthropic organizations, positioning it at the forefront of healthcare innovation.